ACC Cardio-oncology Course Equips Clinicians, Researchers with Tools to Improve Cardiovascular Care for Cancer Patients

The conference aims to ensure the care team stays at the leading edge of this evolving field

The American College of Cardiology (ACC) will host the annual Advancing the Cardiovascular Care of the Oncology Patient course on April 14-16, 2023, in Washington, DC. The course is intended for all members of the interprofessional care team—including cardiologists, oncologists, pharmacists and nurses—and aims to equip the global cardio-oncology community with the tools they need to improve patient care.

Ana Barac, MD, PhD, FACC, and Bonnie Ky, MD, MSCE, FACC, will serve as co-directors for the course, which will be available both in-person and online. The course will bring together clinicians and researchers from across the globe to share emerging strategies and best practices for managing the cardiovascular health of cancer patients.

“I am proud to say that the ACC course has set the standards for cardio-oncology education, including joint presentations of oncologists and cardiologists modeling real-life patient care and collaboration across CV and oncology teams,” Barac said. “This year, our theme is collaboration and innovation through science and for our patients. I am very excited about the first-ever joint sessions with the American Society of Clinical Oncology and the American Society of Hematology that are a testament of the commitment of our professional societies to collaborate and address the gaps that exist across specialties.”

Can’t Miss Sessions:

  • Pharmacology Essentials for Cardio-Oncology Practice
  • How to Build and Grow a Cardio-Oncology Program
  • The Global Burden and Significance of Cancer and Cardiovascular Disease
  • Cardiovascular Disparities in Cancer Patients and Survivors: Strategies to Implement Inclusive, Equitable Care
  • Physical Activity Interventions in Our Cancer Patients and Survivors: Why, When, and How?

Posters

The following abstract titles are a selection of posters being presented during the conference. All ACC Advancing the Cardiovascular Care of the Oncology Patients posters and abstracts are embargoed until Friday, April 14, 2023, at 9 a.m. ET.

  • Racial Disparities in Cardiotoxicity Following Cancer Treatment: A Systematic Review and Meta-Analysis
  • Assessment of Detectable Atherosclerosis on Computed Tomography Imaging in Breast Cancer Patients Entering Treatment
  • Prevalence of Statin Use and Dyslipidemia Screening for Secondary Cardiovascular Prevention in Patients with Cancer
  • SGLT2 Inhibitors are Associated with a Lower Risk of Malnutrition and Cachexia in Patients with Heart Failure Receiving Anthracycline Treatment

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.